Trials / Conditions / Resectable Non-small Cell Lung Cancer

Resectable Non-small Cell Lung Cancer

11 registered clinical trials studyying Resectable Non-small Cell Lung Cancer — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectab NCT07318636	The First Affiliated Hospital of Guangzhou Medical University	Phase 1
Not Yet Recruiting	A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib F NCT07038460	Wen-zhao ZHONG	Phase 2
Not Yet Recruiting	Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable No NCT06946836	Shanghai Pulmonary Hospital, Shanghai, China	Phase 2
Not Yet Recruiting	Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC NCT06607926	Xuanwu Hospital, Beijing	N/A
Not Yet Recruiting	A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC NCT06485557	Tang-Du Hospital	Phase 3
Active Not Recruiting	A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than t NCT06161441	Regeneron Pharmaceuticals	Phase 2
Recruiting	An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemothe NCT06169956	Bristol-Myers Squibb	—
Withdrawn	Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab NCT05472623	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 2
Recruiting	Study of Novel Treatment Combinations in Patients With Lung Cancer NCT05633667	Gilead Sciences	Phase 2
Active Not Recruiting	AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC NCT05247684	Akeso	Phase 2
Completed	Mechanism of Action Trial of ColoAd1 NCT02053220	Akamis Bio	Phase 1